Autosomal dominant Parkinson disease 4

This study tested whether adding the immunotherapy drug pembrolizumab to standard hormone therapy (enzalutamide plus ADT) could help men with metastatic hormone-sensitive prostate cancer live longer or delay cancer growth. The trial enrolled 186 Chinese men and was stopped early …

This trial is testing whether combining the immunotherapy drug pembrolizumab with other experimental agents can help people with advanced melanoma whose cancer has stopped responding to standard anti-PD-1 treatment. The study includes several treatment arms, each pairing pembroli…

This phase 2 trial tests a new drug combination called MK-4280A (favezelimab plus pembrolizumab) against standard chemotherapy in people with classical Hodgkin lymphoma that has come back or stopped responding to treatment. About 200 participants will be randomly assigned to rece…

This phase 3 trial tests whether a new drug combination (MK-7684A) plus chemoradiotherapy helps people with stage III non-small cell lung cancer live longer than the current standard treatment. About 611 participants will receive either the new combo or durvalumab. The study is a…

This early-phase study tests an experimental drug called MK-6837, given alone or with another drug (pembrolizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug sh…

This study tested several combinations of the immunotherapy drug pembrolizumab (Keytruda) with other experimental drugs in people with stage III melanoma that can be surgically removed. The goal was to see if these combinations are safe and more effective than current treatments …

This large Phase 3 trial tested whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard trastuzumab plus chemotherapy could improve outcomes for people with advanced HER2-positive stomach or gastroesophageal junction cancer. The study enrolled 738 participants …

This large phase 3 trial tested whether adding the immunotherapy drug pembrolizumab (Keytruda) and the targeted therapy olaparib (Lynparza) to standard chemotherapy helps women with advanced ovarian cancer that does not have a BRCA mutation. Over 1,300 participants received eithe…

This phase 2 trial tests whether adding experimental drugs (MK-4830, boserolimab, or lenvatinib) to the standard combination of pembrolizumab and chemotherapy can improve outcomes for people with extensive-stage small cell lung cancer. Participants receive one of these new combin…

This phase 3 trial tests whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemoradiotherapy helps people with esophageal cancer live longer and delay recurrence. About 700 participants who cannot have surgery will receive either pembrolizumab or a placeb…

This study tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy before and after bladder removal surgery helps people with muscle-invasive bladder cancer live longer without the cancer coming back. About 900 participants took part. The goal was to s…

This early-phase trial tests an experimental oral drug, MK-6598, both by itself and in combination with the immunotherapy pembrolizumab (Keytruda) in adults with advanced or metastatic solid tumors. The main goals are to check safety, find the right dose, and see early signs of t…

This clinical trial tests whether adding the immunotherapy drug pembrolizumab (Keytruda) to the standard hormone therapy enzalutamide (Xtandi) helps men with a type of advanced prostate cancer called metastatic castration-resistant prostate cancer (mCRPC). The study includes men …

This phase 3 trial tested whether adding the drug olaparib (Lynparza) to standard treatment with pembrolizumab (Keytruda) and chemotherapy helps people with advanced nonsquamous lung cancer live longer without their disease worsening. Over 1,000 participants received either olapa…

This clinical trial is testing a combination of two drugs—an immunotherapy (pembrolizumab/quavonlimab) and a targeted therapy (lenvatinib)—as a first treatment for people with advanced hepatocellular carcinoma, a type of liver cancer that cannot be removed by surgery. The study a…

This study tested whether adding another drug to the immunotherapy pembrolizumab (Keytruda) can help people with advanced non-small cell lung cancer whose disease got worse after initial treatment. 128 participants received one of three drug combinations. The goal was to see if t…

This study tested whether matching drug combinations to specific biomarkers in advanced non-small cell lung cancer could improve response. 245 patients who had not received prior treatment were grouped by two biomarkers (GEP and TMB) and given pembrolizumab plus another drug. The…

This study tested a new under-the-skin shot version of the cancer drug pembrolizumab (Keytruda) in 142 people with advanced solid tumors. The goal was to see how well the body absorbs the drug compared to the standard IV infusion. Researchers also checked for side effects and how…

This study tested whether adding other treatments to the drug pembrolizumab can help people with advanced melanoma that hasn't been treated before. Researchers checked safety and how many people's tumors shrank or disappeared. The trial involved 335 participants and was part of a…

This Phase 3 trial tested a new drug combination called MK-4280A (favezelimab plus pembrolizumab) against standard treatments (regorafenib or TAS-102) in 441 people with advanced colorectal cancer that had stopped responding to prior therapy. The goal was to see if the new combin…

This Phase 3 trial tested whether combining pembrolizumab (an immunotherapy) with epacadostat (a drug that boosts the immune response) works better than standard drugs (sunitinib or pazopanib) for people with advanced kidney cancer that hasn't been treated before. The study enrol…

This study tested a combination of two drugs, lenvatinib and pembrolizumab, in 611 people with advanced cancers like breast, ovarian, stomach, colorectal, brain, bile duct, or pancreatic cancer that had stopped responding to standard treatments. The goal was to see if the combo c…

This phase 3 trial tested whether adding lenvatinib and pembrolizumab to standard chemotherapy helps people with advanced gastroesophageal cancer live longer. About 895 participants received either the new combination or chemo alone. The study is complete, and results will show i…

This large Phase 3 trial tested whether adding the immunotherapy pembrolizumab (Keytruda) to standard hormone therapy (enzalutamide plus ADT) could improve outcomes for men with metastatic hormone-sensitive prostate cancer. Over 1,200 participants were enrolled. The study was unb…

This large phase 3 trial tested whether the immunotherapy drug pembrolizumab (Keytruda) can prevent liver cancer from coming back in people who had successful surgery or ablation. 959 participants received either pembrolizumab or a placebo every three weeks. The study measured ho…

This Phase 3 trial tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (gemcitabine and cisplatin) helps people with advanced bile duct cancer live longer. The study enrolled 158 Chinese adults with cancer that had spread or could not be removed by…

This study tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (gemcitabine/cisplatin) helps people with advanced bile duct or gallbladder cancer live longer. Over 1,000 participants received either the combination or chemo plus a placebo. The goal…

This study tested a combination of two drugs, lenvatinib and pembrolizumab, against standard chemotherapy in 827 people with advanced endometrial cancer that had worsened after initial treatment. The goal was to see if the combo could delay cancer growth and extend life. Results …

This phase 3 trial tested the drug pembrolizumab (Keytruda) against a placebo in 1,177 people with early-stage non-small cell lung cancer who had already had surgery. The goal was to see if pembrolizumab could delay the cancer from coming back. Participants received either the dr…

This phase 2 trial tested a combination of two drugs, favezelimab and pembrolizumab (MK-4280A), in 163 people with either a type of skin cancer (cutaneous squamous cell carcinoma) or endometrial cancer. The goal was to see if the treatment could shrink or eliminate tumors. The st…

This study tested a combination of two drugs—NT-I7 (efineptakin alfa) and pembrolizumab (Keytruda)—in 215 people with advanced solid tumors that had stopped responding to treatment. The goal was to check safety, find the right dose, and see if the combo could shrink tumors. The t…

This phase 3 trial tested whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy before and after surgery helps people with stomach or gastroesophageal junction cancer. Over 1,000 participants received either pembrolizumab plus chemo or placebo pl…

This Phase 3 trial tested whether the immunotherapy drug pembrolizumab (Keytruda) could help prevent kidney cancer from coming back after surgery. Nearly 1,000 participants who had their kidney removed due to renal cell carcinoma received either pembrolizumab or a placebo. The st…

This study tested whether adding the drug pembrolizumab to standard chemotherapy helps Chinese adults with stomach or gastroesophageal junction cancer. Participants received the drug combination or a placebo before and after surgery. The goal was to see if the combination improve…

This large Phase 3 trial tested adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy for people with advanced stomach cancer that cannot be removed by surgery. Over 1,500 participants received either pembrolizumab plus chemo or a placebo plus chemo. The…

This study tested whether adding the immunotherapy drug pembrolizumab to standard chemoradiation helps people with high-risk, locally advanced cervical cancer live longer without their cancer growing. About 1,060 participants received either pembrolizumab or a placebo alongside t…

This phase 3 trial tested whether adding lenvatinib to pembrolizumab helps people with untreated advanced non-small cell lung cancer whose tumors have PD-L1 levels of 1% or higher. Over 600 participants received either the combination or pembrolizumab alone. The study measured ho…

This completed Phase 3 trial tested whether the immunotherapy drug pembrolizumab (Keytruda) works better than the targeted drug brentuximab vedotin (Adcetris) for people with classical Hodgkin lymphoma that has relapsed or not responded to prior therapy. 304 participants were ran…

This completed phase II study tested a combination of two drugs—tadalafil (Cialis) and pembrolizumab (Keytruda)—in 7 adults with advanced head and neck cancer that had spread or come back. The goal was to see if the combination was safe and could help control the disease. Because…

This study tested whether adding lenvatinib to pembrolizumab works better than pembrolizumab alone for people with advanced melanoma that hasn't been treated yet. About 674 adults with stage III or IV melanoma took part. The goal was to see if the combination helps people live lo…

This phase 3 trial tested whether adding the targeted therapy lenvatinib to a standard combination of immunotherapy (pembrolizumab) and chemotherapy could help people with a common type of advanced lung cancer live longer. The study enrolled 761 adults with metastatic nonsquamous…

This study tested whether adding lenvatinib to pembrolizumab (immunotherapy) helps people with advanced bladder cancer live longer or keep their cancer from growing. It included 505 people whose cancer had spread and who could not take the chemotherapy drug cisplatin. The trial w…

This study tested a combination of two drugs, lenvatinib and pembrolizumab, against the usual treatments for people with advanced colorectal cancer that had spread and stopped responding to prior therapy. About 563 adults took part. The goal was to see if the new combo helped peo…

This study tested whether adding pembrolizumab (an immunotherapy) to lenvatinib (a targeted therapy) works better than lenvatinib alone for people with advanced liver cancer. About 794 adults took part. The combination did not significantly improve how long patients lived or dela…

This large Phase 3 trial tested whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemoradiation helps people with locally advanced head and neck cancer live longer without the disease getting worse. Over 800 participants received either pembrolizumab plu…

This phase 3 trial tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy helps women with advanced cervical cancer live longer and keep the disease from growing. Over 600 women with persistent, recurrent, or metastatic cervical cancer took part. The …

This study tested whether adding lenvatinib to pembrolizumab works better than pembrolizumab alone for people with advanced melanoma who haven't had prior treatment. It involved 131 Chinese participants with stage III or IV melanoma that could not be removed by surgery. The goal …

This study tested several combinations of the immunotherapy drug pembrolizumab (Keytruda) with other drugs in 90 people with advanced esophageal cancer that had already progressed after one prior treatment. The goal was to see if these combinations are safe and can shrink tumors …

This study tested whether adding an experimental drug (epacadostat) to an immunotherapy (pembrolizumab) works better than standard chemotherapy for people with advanced head and neck cancer that has come back or spread. 89 adults took part. The main goal was to see how many patie…

This study tested whether a combination of two drugs, lenvatinib and pembrolizumab, could help people with head and neck cancer that has returned or spread and is no longer responding to standard treatments. About 408 participants were randomly assigned to receive the combination…

This study tested a combination of two drugs, pembrolizumab and lenvatinib, in 160 people with a rare type of advanced kidney cancer (non-clear cell renal cell carcinoma) that had not been treated before. The goal was to see if the drugs could shrink tumors. The study found that …

This phase 3 trial tests a new drug combination, MK-4280A (favezelimab plus pembrolizumab), against standard treatments (regorafenib or TAS-102) in 94 Chinese adults with advanced, PD-L1 positive colorectal cancer that has worsened after prior therapy. The main goal is to see if …

This study tested a combination of the immunotherapy drug pembrolizumab with two investigational drugs (MK-4830 or MK-0482) in 102 people with advanced non-small cell lung cancer that had not been treated before and tested positive for a protein called PD-L1. The main goal was to…

This early-phase study tested a new drug called boserolimab (MK-5890), either alone or combined with the immunotherapy pembrolizumab (KEYTRUDA), in 182 adults with advanced solid tumors, including lung and breast cancers. The main goals were to check safety and how the drug moves…

This study tested a new drug (MK-1454) injected directly into tumors, combined with the immunotherapy pembrolizumab, for people with advanced head and neck cancer that had not been treated before. The goal was to see if the combination worked better than pembrolizumab alone. 18 a…

This early-phase study tested an experimental drug (MK-1454) injected directly into tumors, either alone or with pembrolizumab (Keytruda), in 156 people with advanced solid tumors or lymphomas. The main goals were to find the safest dose and check for side effects. The study also…

This completed phase 1/2 trial tested the safety and effectiveness of pembrolizumab (Keytruda) alone or combined with other drugs (quavonlimab or lenvatinib) in 56 people with melanoma that had spread to the brain. Participants had not received steroids recently and were neurolog…

This early-stage trial tested a new drug called vibostolimab, either alone or combined with other cancer drugs, in 474 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the right dose, and see if the dr…

This phase 3 trial tested whether adding the immunotherapy drug pembrolizumab (Keytruda) to best supportive care helps Asian patients with advanced liver cancer live longer. 453 patients who had already received one prior treatment were randomly assigned to get either pembrolizum…

This Phase 3 trial tested whether adding the targeted drug lenvatinib to standard chemotherapy plus the immunotherapy pembrolizumab helps people with advanced nonsquamous non-small cell lung cancer live longer without their cancer growing. The study enrolled 201 adults in China w…

This study aims to develop computer models that can help diagnose and monitor Parkinson's disease by analyzing eye movements and walking patterns. Researchers will collect data from 100 people with Parkinson's or similar conditions using special devices. The goal is to make diagn…

This study tested whether a single infusion of zoledronic acid (Reclast) can prevent fractures in men and women aged 60 and older with Parkinson's disease or related conditions. Over 2,700 participants were randomly assigned to receive either the drug or a placebo, and were follo…

This study tested whether infusing tiny bubbles of oxyhydrogen gas could help people with Parkinsonism. 35 adults received the infusion alongside their usual care. Researchers measured changes in disease severity, thinking ability, and quality of life. The goal was to see if this…

This trial tests whether a machine vision system can accurately rate the motor symptoms of Parkinson's disease, as measured by the MDS-UPDRS Part III scale. Researchers will record videos of patients performing standardized tasks and use machine learning to develop an AI rating m…

This study looked at 115 adults with advanced non-small cell lung cancer to see if muscle loss (sarcopenia) and a blood-based score called CTI affect how well immunotherapy works. Researchers reviewed medical records to measure muscle on CT scans and calculate CTI from routine bl…

This completed study looked at over 2,500 people with Parkinson's disease who were admitted to the hospital through the emergency room. Researchers wanted to find the main reasons for these hospital stays and compare them to people of the same age without Parkinson's. The goal wa…